CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 2	$ 78,647	$ 1,508	$ 88,010
Operating expenses:
Cost of sales - product		866		1,753
Cost of sales - intangible amortization		8		793
Cost of sales - sale of COPIKTRA license and related assets		31,187		31,187
Research and development	9,325	10,955	27,951	31,223
Selling, general and administrative	5,523	20,614	18,455	55,660
Total operating expenses	14,848	63,630	46,406	120,616
(Loss) income from operations	(14,846)	15,017	(44,898)	(32,606)
Other expense				(1,313)
Interest income	40	19	141	497
Interest expense	(7,980)	(1,898)	(9,962)	(14,440)
Net (loss) income	$ (22,786)	$ 13,138	$ (54,719)	$ (47,862)
Net (loss) income per share-basic	$ (0.13)	$ 0.08	$ (0.31)	$ (0.32)
Net (loss) income per share-diluted	$ (0.13)	$ 0.08	$ (0.31)	$ (0.32)
Weighted average common shares outstanding used in computing:
Net (loss) income per share-basic	179,861	169,510	174,524	147,766
Net (loss) income per share-diluted	179,861	169,760	174,524	147,766
Net (loss) income	$ (22,786)	$ 13,138	$ (54,719)	$ (47,862)
Unrealized (loss) on available-for-sale securities	(12)		(26)	(14)
Comprehensive (loss) income	(22,798)	13,138	(54,745)	(47,876)
Product revenue, net
Revenue:
Total revenue		5,829		15,098
License and collaboration revenue
Revenue:
Total revenue		2,818		2,912
Copiktra license and related assets
Revenue:
Total revenue		$ 70,000	902	$ 70,000
Transition Services Revenue
Revenue:
Total revenue	$ 2		$ 606